Annotation Detail

Information
Associated Genes
CD274
Associated Variants
CD274 EXPRESSION
CD274 EXPRESSION
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3≥50%, TC2≥5% and <50%, TC1≥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3≥10%, IC2≥5% and <10%, IC1≥1% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 0·49 [0·22-1·07; p=0·068], TC2/3 or IC2/3 HR 0·54 [0·33-0·89; p=0·014], TC1/2/3 or IC1/2/3 HR 0·59 [0·40-0·85; p=0·005], TC0 and IC0 HR 1·04 [0·62-1·75; p=0·871]) but not progression free survival or overall response rate.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1172
Gene URL
https://civic.genome.wustl.edu/links/genes/11335
Variant URL
https://civic.genome.wustl.edu/links/variants/276
Rating
4
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Atezolizumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26970723
Drugs
Drug NameSensitivitySupported
AtezolizumabSensitivitytrue